Tandem Diabetes stock trades up, here is why

What happened?

Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) jumped 10.4% in the morning session after the company announced U.S. Food and Drug Administration clearance of its Tandem Mobi system as the world's first and only tubeless automated insulin delivery system wearable for up to seven days. 

According to the company's announcement, Tandem Diabetes Care plans to commercially launch the newly cleared device in the first half of 2027. The milestone is significant because extended wear duration and a tubeless form factor address key patient preferences in diabetes management, potentially bolstering the company's competitive position and opening new commercial growth opportunities upon release.

Is now the time to buy Tandem Diabetes? Access our full analysis report here, it’s free.

What is the market telling us

Tandem Diabetes’s shares are extremely volatile and have had 48 moves greater than 5% over the last year. But moves this big are rare even for Tandem Diabetes and indicate this news significantly impacted the market’s perception of the business.

The biggest move we wrote about over the last year was 9 months ago when the stock gained 30.2% on the news that the company reported better-than-expected fourth-quarter financial results. 

The medical device maker posted quarterly sales of $290.4 million, a 15% increase year-on-year that surpassed analyst estimates. The company also recorded a much smaller-than-expected loss of just one cent per share. While this was a slight decline from the one-cent profit reported in the same quarter last year, it handily beat forecasts. Investors appeared to focus on the strong quarterly performance and improved operating margins, driving the stock higher despite the company issuing a 2026 sales forecast that was slightly below market expectations.

Tandem Diabetes is down 8.5% since the beginning of the year, and at $19.71 per share, it is trading 30.2% below its 52-week high of $28.26 from February 2026. Investors who bought $1,000 worth of Tandem Diabetes’s shares 5 years ago would now be looking at only $143.41.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.